RedHill Biopharma (RDHL) files for 6.47M share offering by selling stockholders Jan 22, 2026 04:09PM
RedHill advances RHB-102 development for GLP-1 side effects Jan 5, 2026 07:02AM
RedHill reports opaganib reduces venetoclax-resistant leukemia cells by 50% Dec 15, 2025 07:03AM
RedHill Biopharma secures final $10.5 million court judgment Nov 4, 2025 12:02PM
RedHill wins $10.5 million court judgment against Kukbo Co. Nov 4, 2025 09:30AM


Oct 22, 2025 04:51PM RedHill Biopharma appeals Nasdaq delisting notice
Oct 20, 2025 09:05AM Cumberland Pharmaceuticals partners with RedHill for Talicia commercialization
Oct 6, 2025 08:01AM RedHill licenses Talicia to Middle East partner for $1.8M deal
Sep 29, 2025 07:02AM RedHill Biopharma wins $10 million court judgment on appeal
Aug 20, 2025 09:03AM RedHill Biopharma wins $1.8M in legal costs from New York court
Aug 18, 2025 09:03AM RedHill receives $1.1 million in licensing payments for Talicia
Jul 21, 2025 09:01AM RedHill gets FDA guidance for Crohn's disease drug trial design
Jul 1, 2025 12:01PM RedHill Biopharma (RDHL) Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer
Apr 28, 2025 07:05AM RedHill Biopharma (RDHL) Secures Allowance of Chinese Patent Application for RHB-107
Apr 17, 2025 04:08PM RedHill Biopharma (RDHL) Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
Apr 16, 2025 07:02AM RedHill Biopharma's (RDHL) Positive Opaganib Weight Loss & Diabetes Data Published
Mar 18, 2025 07:00AM RedHill Biopharma (RDHL) to Submit Talicia for UK Marketing Authorisation
Feb 25, 2025 07:04AM RedHill Biopharma (RDHL) Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties
Feb 4, 2025 07:02AM RedHill Biopharma (RDHL) Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer
Dec 10, 2024 07:06AM RedHill Biopharma (RDHL) Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
Dec 2, 2024 07:00AM RedHill Biopharma (RDHL) Awarded Judgment of Approximately $8M Plus Costs by NY Supreme Court
Oct 22, 2024 07:01AM RedHill Biopharma (RDHL) Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib
Oct 14, 2024 07:01AM RedHill Biopharma (RDHL) Secures BARDA Funding to Advance Opaganib for Ebola Treatment
Oct 1, 2024 07:08AM RedHill Biopharma (RDHL) and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
Sep 30, 2024 07:05AM RedHill (RDHL) Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
Sep 5, 2024 07:01AM RedHill Biopharma (RDHL) Regains Nasdaq Compliance
Sep 3, 2024 07:06AM RedHill Biopharma (RDHL): New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality
Aug 26, 2024 07:00AM RedHill's (RDHL) Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma
Aug 19, 2024 07:00AM RedHill Biopharma (RDHL) Announces Positive Obesity and Diabetes Results with Opaganib
Aug 16, 2024 07:01AM RedHill Biopharma (RDHL) to Implement ADS Ratio Change
Jul 22, 2024 07:02AM RedHill Biopharma (RDHL) Strengthens Cash Balance, Settles Obligations and Removes Talicia Lien
Jul 9, 2024 08:04AM RedHill Biopharma (RDHL) Terminates License Agreement for Aemcolo